GLP-1 Comparison Chart
GLP-1 comparison chart: pick up to 3 GLP-1 medicines and see their FDA label facts side by side, plus what each one costs.
The basics
5 of 5 differ
Average market cost
3 of 4 differ
US prices for about one month, checked Oct 6, 2026. List prices are from the makers and TrumpRx.gov, and GoodRx for Zepbound pens. Self-pay prices are from the makers. Cash prices are from GoodRx and SingleCare. They are for one pack and vary by pharmacy. Price varies by strength. Insurance and coupons change what people pay.
Approved for
4 of 6 differ
How it is taken
6 of 6 differ
• Single-dose prefilled syringe
• Single-dose vial
• Multi-dose vial
• Multi-dose pen (one patient), KwikPen
• Swallow whole
After first use: Room temperature or fridge, 56 days
Single-dose syringe, until use: Fridge; if needed out of the fridge up to 28 days
Never freeze
Multi-dose vial or KwikPen, before first use: Fridge until expiration; 30 days if kept at room temperature
Multi-dose vial or KwikPen, after first use: Fridge or room temperature; throw away after 30 days or 4 weekly shots
Never freeze
Safety on the label
4 of 5 differ
+1 more
constipation+3 more
constipation, dyspepsia, abdominal pain+9 more
dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux disease, flatulence, hair lossSee all
• Risk of Thyroid C-Cell Tumors• Acute Pancreatitis
• Diabetic Retinopathy Complications
• Never Share an OZEMPIC Pen Between Patients
• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin
• Acute Kidney Injury Due to Volume Depletion
• Severe Gastrointestinal Adverse Reactions
• Hypersensitivity Reactions
• Acute Gallbladder Disease
• Pulmonary Aspiration During General Anesthesia or Deep Sedation
See all
• Risk of Thyroid C-Cell Tumors• Acute Pancreatitis
• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin
• Hypersensitivity Reactions
• Acute Kidney Injury Due to Volume Depletion
• Severe Gastrointestinal Adverse Reactions
• Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy
• Acute Gallbladder Disease
• Pulmonary Aspiration During General Anesthesia or Deep Sedation
• Never Share a MOUNJARO KwikPen Between Patients
See all
• Risk of Thyroid C-Cell Tumors• Acute Pancreatitis
• Severe Gastrointestinal Reactions
• Acute Kidney Injury Due to Volume Depletion
• Hypoglycemia
• Hypersensitivity Reactions
• Diabetic Retinopathy Complications in Patients with Type 2 Diabetes
• Acute Gallbladder Disease
• Pulmonary Aspiration During General Anesthesia or Deep Sedation
• Serious allergic reaction to semaglutide or any ingredient
• Serious allergic reaction to tirzepatide or any ingredient
• Serious allergic reaction to orforglipron or any ingredient
Discontinue OZEMPIC in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide.
Based on animal studies, may cause fetal harm.
May cause fetal harm. When pregnancy is recognized, discontinue FOUNDAYO.
The label itself
2 of 2 differ
Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1.
Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1.
FOUNDAYO is a GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor.
From each medicine's FDA label on DailyMed, read Oct 6, 2026, and its Drugs@FDA record. Facts only, not advice.
All 12 at a glance
| Brand | Taken as | Approved for |
|---|---|---|
| Ozempicsemaglutide | ShotOnce weekly Pen or prefilled syringe | Type 2 diabetes, Heart and stroke risk, Kidney |
| Wegovysemaglutide | Shot or pillShot once weekly Pen or syringe Pill once daily | Heart and stroke risk, Weight, MASH liver (shot only) |
| Rybelsus and Ozempic tabletssemaglutide | PillOnce daily | Type 2 diabetes, Heart and stroke risk |
| Mounjarotirzepatide | ShotOnce weekly Pen or vial | Type 2 diabetes, Heart and stroke risk |
| Zepboundtirzepatide | ShotOnce weekly Pen or vial | Weight, Sleep apnea |
| Foundayoorforglipron | PillOnce daily | Weight |
| Saxendaliraglutide | ShotOnce daily | Weight |
| Victozaliraglutide | ShotOnce daily | Type 2 diabetes, Heart and stroke risk |
| Trulicitydulaglutide | ShotOnce weekly | Type 2 diabetes, Heart and stroke risk |
| ByettaexenatideBrand no longer marketed in the US | ShotTwice daily | Type 2 diabetes |
| Xultophyinsulin degludec and liraglutide | ShotOnce daily | Type 2 diabetes |
| Soliquainsulin glargine and lixisenatide | ShotOnce daily | Type 2 diabetes |
Paste this code into your page. It shows the GLP-1 comparison chart with one plain credit link.
Learn
What this chart is and where it comes from
Tap a medicine to add it. Each pick takes its own color and a number. Tap it again to take it out. The rows sit in six sections, and each section says how many of its rows differ between your picks. Every label fact comes from the maker's FDA label, and the last section links to that label with its version and date.
GLP-1 itself is a gut hormone. After a meal it raises insulin and lowers glucagon. It also slows stomach emptying and food intake, a 2018 review explains. The medicines in this chart act on its receptor.
The chart shows the medicine, the maker, how it is taken, how often the label says to take it, and the uses the FDA approved. It also shows if the label has a boxed warning, which is a warning set in a box at the top of the label.
Source: Drucker DJ, Cell Metabolism 2018, PMID 29617641.
How to read the chart
- The basics shows the medicine inside, what it acts on, the maker, the year the FDA first approved the brand, and the ages on the label. Most act on the GLP-1 receptor alone, while tirzepatide acts on GIP and GLP-1. Two products mix a GLP-1 medicine with insulin.
- Average market cost shows the US list price per month, the maker's self-pay price, a typical pharmacy cash price for one pack, and any generic version. Insurance and coupons change what people pay.
- Approved for puts a check mark on each use that section 1 of the label lists. "Injection only" or "tablets only" means the label limits that use to one form.
- How it is taken shows shot or tablet, the device, how often, the tablet rules, the half-life and how to store it.
- Safety on the label shows the boxed warning, the most common side effects, the list of label warnings, who should not use it, and what the label says about pregnancy.
- The label itself quotes how the medicine works, from section 12.1, and links to the label on DailyMed, the National Library of Medicine's label site.
Same medicine, different brands and forms
Some brands hold the same molecule. Ozempic, Wegovy and Rybelsus all contain semaglutide. Mounjaro and Zepbound both contain tirzepatide. Saxenda and Victoza both contain liraglutide.
The brands differ in their labels. The approved uses differ, and so can the form and how often it is taken. The pages on Ozempic vs Wegovy and Mounjaro vs Zepbound show this line by line. For the two molecules side by side, see tirzepatide vs semaglutide.
Most GLP-1 medicines are shots. Three labels in the chart cover tablets: Foundayo, Rybelsus and Ozempic tablets, and Wegovy tablets. The GLP-1 pill page puts the tablet labels side by side.
The Rybelsus label now also covers Ozempic tablets, so they share one column in the chart. Ozempic shots now come in a pen or in a single-use prefilled syringe, the Ozempic label says.
Sources: the Ozempic and Rybelsus labels on DailyMed, read October 6, 2026.
How the chart is checked and dated
FDA labels are updated often. Below is each label's version on DailyMed when we read it, with earlier versions. The Mounjaro and Zepbound labels both have a new version dated late August 2026.
| Label | Version in the chart | Posted on DailyMed | Earlier versions (posted) |
|---|---|---|---|
| Ozempic | v20 | Jun 10, 2026 | v19 (May 21, 2026); v18 (Jan 26, 2026); v17 (Nov 17, 2025) |
| Wegovy | v19 | Jun 30, 2026 | v18 (May 22, 2026); v17 (Apr 02, 2026); v16 (Mar 05, 2026) |
| Rybelsus and Ozempic tablets | v14 | Aug 19, 2026 | v13 (May 20, 2026); v13 (May 18, 2026); v12 (Feb 23, 2026) |
| Mounjaro | v40 | Sep 02, 2026 | v38 (May 06, 2026); v36 (Feb 25, 2026); v35 (Feb 09, 2026) |
| Zepbound | v40 | Sep 02, 2026 | v38 (May 06, 2026); v37 (Mar 03, 2026); v36 (Feb 26, 2026) |
| Foundayo | v10 | Aug 13, 2026 | v5 (Apr 03, 2026) |
| Saxenda | v22 | Jun 15, 2026 | v21 (Mar 11, 2026); v20 (Nov 17, 2025); v19 (Jun 12, 2025) |
| Victoza | v31 | Nov 17, 2025 | v30 (Jun 12, 2025); v29 (Feb 24, 2025); v28 (Nov 15, 2024) |
| Trulicity | v62 | Aug 10, 2026 | v60 (Mar 25, 2026); v59 (Dec 22, 2025); v57 (Jun 30, 2025) |
| Byetta | v26 | Sep 08, 2025 | v25 (Jun 05, 2025); v24 (Nov 13, 2024); v22 (Aug 20, 2024) |
| Xultophy | v14 | Nov 17, 2025 | v13 (Jun 13, 2025); v12 (Nov 15, 2024); v11 (May 24, 2024) |
| Soliqua | v25 | Mar 20, 2026 | v23 (Aug 01, 2025); v22 (Jun 13, 2025); v19 (Nov 14, 2024) |
We plan to read every label again each month. When a label has a new version, its row is checked again by a person before the chart changes.
On October 6, 2026 we saved each of the 12 labels from DailyMed. A script then checked all 115 label quotes on this site against those saved files, word for word. It found 0 that did not match.
We also looked up each label's FDA application number in Drugs@FDA, the FDA's approval database. All 12 have an approval record there. One brand, Byetta, is marked there as discontinued. It is no longer marketed in the US as of September 3, 2025, when the FDA withdrew its approval at the maker's request, a Federal Register notice says. The notice also says stock on hand that day may still be dispensed until it runs out, expires or otherwise no longer meets the law, whichever comes first. Its last label is still on DailyMed, so its label facts stay in the chart, marked "Brand no longer marketed in the US". A generic exenatide from Amneal has its own FDA label on DailyMed.
Sources: Drugs@FDA; Federal Register notice 2025-14683, August 4, 2025; DailyMed.
What this chart leaves out
This site does not rank these medicines, give doses or say which one is better. It does not list strengths, doses or weight loss numbers. Each label lists warnings, side effects and who should not take the medicine. Read the full label, and ask your prescriber about your own care.
Two older brands, Bydureon BCise and Adlyxin, had no current label on DailyMed when we searched. They are not in the chart, because each fact here must come from a current label. The list of GLP-1 drugs shows what that search and Drugs@FDA found.
Generic liraglutide and generic exenatide also have FDA labels from other makers. The list of GLP-1 drugs counts them.
Questions
What are the GLP-1 medications?
Counting each GLP-1 medicine once, the FDA labels in this chart hold 7: dulaglutide, exenatide, liraglutide, lixisenatide, orforglipron, semaglutide and tirzepatide. Lixisenatide comes only mixed with an insulin, in Soliqua, and liraglutide also comes mixed with one, in Xultophy. Tirzepatide acts on GIP as well as GLP-1.
How many GLP-1 drugs are there?
On October 6, 2026, this chart had 12 brand labels, each the newest version on DailyMed. Counting each GLP-1 medicine once, they hold 7. Two of those labels, Xultophy and Soliqua, pair a GLP-1 medicine with an insulin. Generic liraglutide and exenatide add more labels from other makers.
Is tirzepatide a GLP-1?
Yes, tirzepatide acts on the GLP-1 receptor. The Mounjaro and Zepbound labels use the term "GIP receptor and GLP-1 receptor agonist" for it. So it works on two hormone receptors: GIP and GLP-1.
Are GLP-1 drugs available over the counter?
No, not in the US. Every label in this chart is filed with the FDA as a prescription drug label. None is an over-the-counter label.
Which GLP-1 drugs are approved for weight loss?
In this chart, four labels list reducing excess body weight as an approved use: Wegovy, Zepbound, Saxenda and Foundayo. Each label says who it is for. Pick them in the chart to see their labels side by side.
Sources
18 sources with read dates
- Ozempic label on DailyMed, Novo Nordisk, version 20 of 2026-06-01, read 2026-10-06
- Wegovy label on DailyMed, Novo Nordisk, version 19 of 2026-06-18, read 2026-10-06
- Rybelsus and Ozempic tablets label on DailyMed, Novo Nordisk, version 14 of 2026-01-30, read 2026-10-06
- Mounjaro label on DailyMed, Eli Lilly, version 40 of 2026-08-27, read 2026-10-06
- Zepbound label on DailyMed, Eli Lilly, version 40 of 2026-08-28, read 2026-10-06
- Foundayo label on DailyMed, Eli Lilly, version 10 of 2026-07-29, read 2026-10-06
- Saxenda label on DailyMed, Novo Nordisk, version 22 of 2026-02-25, read 2026-10-06
- Victoza label on DailyMed, Novo Nordisk, version 31 of 2025-10-14, read 2026-10-06
- Trulicity label on DailyMed, Eli Lilly, version 62 of 2026-06-16, read 2026-10-06
- Byetta label on DailyMed, AstraZeneca, version 26 of 2025-09-02, read 2026-10-06
- Xultophy label on DailyMed, Novo Nordisk, version 14 of 2025-10-14, read 2026-10-06
- Soliqua label on DailyMed, Sanofi, version 25 of 2026-03-18, read 2026-10-06
- Drugs@FDA application records, US Food and Drug Administration, via the openFDA drugsfda API, read 2026-10-06
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1, Drucker DJ, Cell Metabolism 2018, PMID 29617641, abstract read on PubMed 2026-10-06
- DailyMed label search, National Library of Medicine, searched for Bydureon, Adlyxin, Byetta and exenatide, read 2026-10-06
- Withdrawal of Approval of 39 New Drug Applications (includes Byetta, NDA 021773), Federal Register Vol. 90, No. 147, August 4, 2025, read 2026-10-06, re-read 2026-10-07
- Supplement approval letter, NDA 213051 S-030, US Food and Drug Administration, January 30, 2026, approves the name Ozempic (semaglutide) tablets, read 2026-10-07
- Market figures, all read 2026-10-06: maker list figures from novopricing.com (Novo Nordisk), Lilly's Foundayo disclosure sheet and Sanofi's Soliqua sheet (dated January 2022); TrumpRx.gov; maker self-pay pages (NovoCare, LillyDirect); pharmacy cash figures from GoodRx and SingleCare